191327-30-7

Basic information

• Product Name: 4-(4-Chlorophenoxy)benzenesulfonyl chloride
• Synonyms: 4-(4-Chlorophenoxy)benzenesulphonyl chloride;4-Chloro-4'-(chlorosulphonyl)diphenyl ether;Benzenesulfonylchloride, 4-(4-chlorophenoxy)-
• CAS NO: 191327-30-7
• Molecular Formula: C₁₂H₈Cl₂O₃S
• Molecular Weight: 303.17
• Mol File: 191327-30-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 396.3 °C at 760 mmHg
• Flash Point: 193.5 °C
• Appearance: /
• Density: 1.453 g/cm³
• Vapor Pressure: 3.94E-06mmHg at 25°C
• Refractive Index: 1.603
• CAS DataBase Reference: 4-(4-Chlorophenoxy)benzenesulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Chlorophenoxy)benzenesulfonyl chloride(191327-30-7)
• EPA Substance Registry System: 4-(4-Chlorophenoxy)benzenesulfonyl chloride(191327-30-7)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 191327-30-7(Hazardous Substances Data)

Usage

Description

4-(4-Chlorophenoxy)benzenesulfonyl chloride is an organic chemical compound characterized by its molecular structure that features a sulfonyl chloride group attached to a benzene ring, which in turn is connected to another benzene ring through an oxygen atom. 4-(4-Chlorophenoxy)benzenesulfonyl chloride is known for its reactivity and is commonly utilized in the synthesis of various pharmaceuticals and other organic compounds.

Uses

Used in Pharmaceutical Industry:
4-(4-Chlorophenoxy)benzenesulfonyl chloride is used as a key intermediate in the synthesis of 1-Hydroxy-2-pyridinones, which are known for their excellent in vitro potency in inhibiting matrix metalloproteinase-9 (MMP-9). This inhibition plays a crucial role in the treatment of ischemic stroke, as MMP-9 is an enzyme that contributes to the breakdown of the extracellular matrix and the subsequent damage to blood vessels and brain tissue during stroke.

InChI:InChI=1/C12H8Cl2O3S/c13-9-1-3-10(4-2-9)17-11-5-7-12(8-6-11)18(14,15)16/h1-8H

Upstream product

• 101-84-8 diphenylether 
• 7005-72-3 4-chlorodiphenyl ether 

Downstream Products

• 522623-54-7 2-[4-(4-chloro-phenoxy)-benzenesulfonylamino]-3-hydroxy-propionic acid methyl ester 
• 352209-77-9 4-(4-chlorophenoxy)phenylsulfonyl fluoride 
• 1009121-48-5 4-(4-chlorophenoxy)-N-(2,5-dibromo-pyridin-3-yl)-benzenesulfonamide 
• 226398-39-6 1-(tert-butyl) 4-methyl-4-{[4-(4-chlorophenoxy)phenyl]sulfonyl}-1,4-piperidinedicarboxylate 
• 352209-78-0 1-(tert-butoxycarbonyl)-4-{[4-(4-chlorophenoxy)phenyl]sulfonyl}-4-piperidine carboxylic acid 
• 352209-79-1 1-(tert-butyl) 4-{[4-(4-chlorophenoxy)phenyl]sulfonyl}-4-[(hydroxyamino)carbonyl]-1-piperidine carboxylate 
• 522623-56-9 methyl 2-{(2-aminobenzyl)-[4-(4-chlorophenyloxy)benzene-sulfonyl]amino}-3-hydroxypropionate 
• 597564-87-9 Methyl 3-hydroxy-2-{[4-(4-chlorophenyloxy)benzene-sulfonyl]-(2-nitrobenzyl)amino}proprionate 
• 233755-57-2 4-[4-(4-chloro-phenoxy)-benzenesulfonyl]-1-methoxyacetyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine-3-carboxylic acid 
• 233755-56-1 4-[4-(4-chloro-phenoxy)-benzenesulfonyl]-1-methoxyacetyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine-3-carboxylic acid methyl ester 
• 233755-72-1 4-[4-(4-chlorophenyloxy)benzenesulfonyl]-1-(thien-2-ylcarbonyl)-2,3,4,5-tetrahydro-1H-[1,4]benzodiazepine-3-carboxylic acid 
• 233755-55-0 methyl 2-{[4-(4-chlorophenyloxy)benzenesulfonyl]-[2-(methoxyacetylamino)benzyl]amino}acrylate 
• 233755-59-4 methyl 4-[4-(4-chlorophenyloxy)benzenesulfonyl)-1-(thien-2-ylcarbonyl)-2,3,4,5-tetrahydro-1H-[1,4]benzodiazepine-3-carboxylate 
• 233755-61-8 methyl 4-[4-(4-chlorophenyloxy)benzenesulfonyl]-1-(benzoyl)-2,3,4,5-tetrahydro-1H-[1,4]benzodiazepine-3-carboxylate 

Relevant articles and documents

Radiolabelled MMP selective compounds

The invention is directed to radiolabelled MMP selective compounds, a processes for the preparation thereof, and uses thereof. The derivatives of the invention have formula (I) wherein Y represents O, CH2, (CH2)2, S, NH, o

Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof

The invention relates to compounds of the formula 1: wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder are carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of the formula I or a prodrug, salt of solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.

Arylsulfonylamino hydroxamic acid derivatives

A compound of the formula wherein R1, R2and Q are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal dise